Published in Radiother Oncol on November 15, 2012
Radiogenomics: A systems biology approach to understanding genetic risk factors for radiotherapy toxicity? Cancer Lett (2016) 0.85
Histone deacetylation critically determines T cell subset radiosensitivity. J Immunol (2014) 0.78
Clinical application of micronucleus test: a case-control study on the prediction of breast cancer risk/susceptibility. PLoS One (2014) 0.77
TNFSF10/TRAIL regulates human T4 effector memory lymphocyte radiosensitivity and predicts radiation-induced acute and subacute dermatitis. Oncotarget (2016) 0.75
Compromized DNA repair as a basis for identification of cancer radiotherapy patients with extreme radiosensitivity. Cancer Lett (2016) 0.75
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol (2010) 6.42
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst (2011) 6.11
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res (2009) 4.68
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst (2007) 4.46
Excision margins in high-risk malignant melanoma. N Engl J Med (2004) 3.94
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst (2008) 3.21
Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax (2010) 2.79
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet (2009) 2.75
Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol (2005) 2.59
Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med (2010) 2.56
Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol (2007) 2.32
Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol (2010) 2.27
A minimally invasive assay for individual assessment of the ATM/CHEK2/p53 pathway activity. Cell Cycle (2011) 2.13
The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat (2008) 2.06
Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol (2008) 1.89
Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol (2004) 1.89
β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol (2010) 1.79
TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother Oncol (2005) 1.78
Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med (2010) 1.64
Assessing cancer risks of low-dose radiation. Nat Rev Cancer (2009) 1.53
Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood (2006) 1.51
Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement. J Natl Cancer Inst (2011) 1.45
Effect of breast-duct anatomy and wound-healing responses on local tumour recurrence after primary surgery for early breast cancer. Lancet Oncol (2009) 1.44
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma (2006) 1.44
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer. J Natl Cancer Inst Monogr (2011) 1.34
Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med (2011) 1.31
Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat (2009) 1.29
Gene expression following ionising radiation: identification of biomarkers for dose estimation and prediction of individual response. Int J Radiat Biol (2010) 1.26
Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. J Pathol (2010) 1.25
Establishment of a Radiogenomics Consortium. Int J Radiat Oncol Biol Phys (2010) 1.23
A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med (2008) 1.21
Prognosis of lymph node metastasis in soft tissue sarcoma. Ann Surg Oncol (2004) 1.19
24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol. Curr Med Res Opin (2009) 1.15
Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J Pathol (2011) 1.14
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin Cancer Res (2006) 1.14
ROCK: a breast cancer functional genomics resource. Breast Cancer Res Treat (2010) 1.12
Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir Res (2010) 1.12
Comparative validation of the SP6 antibody to Ki67 in breast cancer. J Clin Pathol (2010) 1.12
Radiation leukemogenesis in mice: loss of PU.1 on chromosome 2 in CBA and C57BL/6 mice after irradiation with 1 GeV/nucleon 56Fe ions, X rays or gamma rays. Part I. Experimental observations. Radiat Res (2009) 1.10
The impact of introducing intensity modulated radiotherapy into routine clinical practice. Radiother Oncol (2005) 1.10
Accelerated partial breast irradiation trials: diversity in rationale and design. Radiother Oncol (2009) 1.09
Haste makes waste: are the data regarding TARGIT-A IORT ready for prime time? Breast Cancer Res Treat (2014) 1.07
Long-term results in elderly patients with differentiated thyroid carcinoma. Cancer (2003) 1.06
Who would have thought a single Ki67 measurement would predict long-term outcome? Breast Cancer Res (2009) 1.04
Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol (2002) 1.04
Detection of defects in myocardial perfusion imaging in patients with early breast cancer treated with radiotherapy. Radiother Oncol (2002) 1.04
High and low dose responses of transcriptional biomarkers in ex vivo X-irradiated human blood. Int J Radiat Biol (2013) 1.00
Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients. Breast Cancer Res Treat (2012) 1.00
Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma. BJU Int (2005) 0.99
Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. Cancer (2005) 0.99
Ionizing radiation biomarkers for potential use in epidemiological studies. Mutat Res (2012) 0.99
Residual DNA and chromosomal damage in ex vivo irradiated blood lymphocytes correlated with late normal tissue response to breast radiotherapy. Radiother Oncol (2011) 0.98
Planning with intensity-modulated radiotherapy and tomotherapy to modulate dose across breast to reflect recurrence risk (IMPORT High trial). Int J Radiat Oncol Biol Phys (2010) 0.98
Splenic marginal zone lymphoma. Blood Rev (2005) 0.97
Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev (2002) 0.97
The European reference condition concept: A scientific and technical approach to identify minimally-impacted river ecosystems. Sci Total Environ (2012) 0.96
The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. Haematologica (2004) 0.96
Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia. Hematol J (2004) 0.96
Intratumoral estrogen disposition in breast cancer. Clin Cancer Res (2010) 0.95
Autonomic nerve trauma at radical hysterectomy: the nerve content and subtypes within the superficial and deep uterosacral ligaments. Reprod Sci (2008) 0.94
Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom. Clin Cancer Res (2006) 0.94
Evidence for significant heritability of apoptotic and cell cycle responses to ionising radiation. Hum Genet (2008) 0.93
Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study. Pulm Pharmacol Ther (2010) 0.92
A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer. Radiother Oncol (2007) 0.92
Non-randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema and tissue fibrosis after radiotherapy for early breast cancer. Radiother Oncol (2004) 0.92
Somatic complex I disruptive mitochondrial DNA mutations are modifiers of tumorigenesis that correlate with low genomic instability in pituitary adenomas. Hum Mol Genet (2012) 0.91
Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity. Radiother Oncol (2012) 0.91
Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer. Breast Cancer Res Treat (2010) 0.91
Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone. Int J Chron Obstruct Pulmon Dis (2010) 0.90
Normal tissue complication probability (NTCP) parameters for breast fibrosis: pooled results from two randomised trials. Radiother Oncol (2013) 0.90
Genomic characterisation of acral melanoma cell lines. Pigment Cell Melanoma Res (2012) 0.89
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. Breast Cancer Res (2012) 0.89
Test of association between variant tgβ1 alleles and late adverse effects of breast radiotherapy. Radiother Oncol (2010) 0.88
Evaluation of implanted gold seeds for breast radiotherapy planning and on treatment verification: a feasibility study on behalf of the IMPORT trialists. Radiother Oncol (2011) 0.88
Large breast size as a risk factor for late adverse effects of breast radiotherapy: is residual dose inhomogeneity, despite 3D treatment planning and delivery, the main explanation? Radiother Oncol (2011) 0.88
Nuclear NF-κB/p65 expression and response to neoadjuvant chemotherapy in breast cancer. J Clin Pathol (2010) 0.88
Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations. Histopathology (2013) 0.88
Immediate breast reconstruction using biodimensional anatomical permanent expander implants: a prospective analysis of outcome and patient satisfaction. Plast Reconstr Surg (2003) 0.87
Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo. Breast Cancer Res (2012) 0.87
Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data. Int J Chron Obstruct Pulmon Dis (2011) 0.87
Homologous recombination mediates cellular resistance and fraction size sensitivity to radiation therapy. Radiother Oncol (2013) 0.87
Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison. Value Health (2012) 0.87
Phase II study of vitamin E and pentoxifylline in patients with late side effects of pelvic radiotherapy. Radiother Oncol (2005) 0.86
Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. Clin Cancer Res (2006) 0.86
Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respir Med (2011) 0.86
Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer. Radiother Oncol (2004) 0.86
Occult primary breast carcinoma presenting as axillary lymphadenopathy. Breast (2002) 0.85